Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Dr. Jonathan Javitt announces MERGER and NEW PROJECTS COMING...
We're at an inflection point in the company where we've signed a term sheet to merge with a NYSE company be publicly listed in the next two quarters. We currently have 50 million dollars in assets. So we're funded through data. We're raising an additional 50 million dollars prior to that listing so that we have the ability to open some new projects that we think will be exciting to the marketplace and to our investors. The funding for the remaining of the SamiAir development is contractually committed by Relief Therapeutics. A Suisse publicly listed company. And we have one hundred million dollar post listing commitment for funding from the GEM Global Markets Fund. So numerous banks are in the process of vetting us. We think that there's strong interest in covering us. And we look forward to seeing you in the marketplace or before.

https://sonix.ai/r/xtrz7PUXeMjvyvbr48n12Ucj/share
MERGER ACQUISITION???

When one public company buys another, stockholders in the company being acquired will generally be compensated for their shares. This can be in the form of cash or in the form of stock in the company doing the buying. Either way, the stock of the company being bought will usually cease to exist.

https://finance.zacks.com/happens-stocks-one-public-company-buys-another-8471.html
REVERSE MERGER???
A reverse merger happens when a publicly trading company merges with a private company and the private company survives, occupying and operating in the publicly traded company's legal shell. The private company takes over controlling ownership of the stock of the public company and management of the company, usually changing the company's name to its own and changing the stock symbol. It is not necessary for both companies to be in the same business; in fact, usually they are in very different businesses.

https://finance.zacks.com/reverse-merger-mean-stocks-1096.html

KODAK MOMENTS COMING???

WHAT NEW PROJECTS??? COULD IT BE...???
There is mounting evidence that pulmonary arterial hypertension (PAH), asthma and chronic obstructive pulmonary disease (COPD) share important pathological features, including inflammation, smooth muscle contraction and remodeling. No existing drug provides the combined potential advantages of reducing vascular- and bronchial-constriction, and anti-inflammation. Vasoactive intestinal peptide (VIP) is widely expressed throughout the cardiopulmonary system and exerts a variety of biological actions, including potent vascular and airway dilatory actions, potent anti-inflammatory actions, improving blood circulation to the heart and lung, and modulation of airway secretions. VIP has emerged as a promising drug candidate for the treatment of cardiopulmonary disorders such as PAH, asthma, and COPD. Clinical application of VIP has been limited in the past for a number of reasons, including its short plasma half-life and difficulty in administration routes. The development of long-acting VIP analogues, in combination with appropriate drug delivery systems, may provide clinically useful agents for the treatment of PAH, asthma, and COPD. This article reviews the physiological significance of VIP in cardiopulmonary system and the therapeutic potential of VIP-based agents in the treatment of pulmonary diseases.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090995/

The COPD and asthma devices market size was estimated at $36.45 billion in 2019, and is anticipated to hit $51.62 billion by 2027, registering a CAGR of 4.3% from 2020 to 2027

https://www.globenewswire.com/news-release/2020/08/11/2076489/0/en/COPD-and-Asthma-Devices-Market-Size-to-Grow-51-62-Billion-By-2027-at-4-3-CAGR.html

Pulmonary Arterial Hypertension Market Worth $9.8 Billion By 2027

https://www.grandviewresearch.com/press-release/global-pulmonary-arterial-hypertension-pah-market-size-report